Different disease progression patterns based on RECIST and CA-125 criteria and the impact on prognosis in patients with ovarian cancer treated with PARP inhibitors.

被引：0
|
作者：
Song, Kun [1 ]
Ma, Yana [1 ]
Bu, Hualei [1 ]
Zhang, Yawen [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17536
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [22] CA-125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A Gynecologic Oncology Group study
    Gardner, G. J.
    Brady, M.
    Bristow, R. E.
    Baser, R. E.
    Markman, M.
    Spriggs, D. R.
    Thaler, H. T.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S26 - S26
  • [23] Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy
    Rodriguez, Noah
    Rauh-Hain, J. Alejandro
    Shoni, Melina
    Berkowitz, Ross S.
    Muto, Michael G.
    Feltmate, Colleen
    Schorge, John O.
    del Carmen, Marcela G.
    Matulonis, Ursula A.
    Horowitz, Neil S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 362 - 366
  • [24] COMPUTED TOMOGRAPHY IS MORE SENSITIVE THAN CA-125 IN DETECTING DISEASE PROGRESSION IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: ANALYSIS OF THE AURELIA TRIAL.
    Lindeman, K.
    Kristensen, G.
    Mirza, M. Raza
    Davies, L.
    Hilpert, F.
    Romero, I.
    Ayhan, A.
    Burges, A.
    Rubio, M. J.
    Raspagliesi, F.
    Huizing, M.
    Creemers, G. J.
    Lykka, M.
    Lee, C.
    Gebski, V.
    Lauraine, E. Pujade
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 37 - 38
  • [25] An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
    Liu, Ping-Yu
    Alberts, David S.
    Monk, Bradley J.
    Brady, Mark
    Moon, James
    Markman, Maurie
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3615 - 3620
  • [26] CA-125 and tumor associated trypsin inhibitor serum levels and their sensitivity in different histological types of epithelial ovarian cancer patients
    Stanojevic, Z
    PoticZecevic, N
    Milutinovic, M
    Filipovic, S
    Filipovic, B
    Tatic, B
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 557 - 560
  • [27] Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients
    Bouvarel, Barnabe
    Colomban, Oliver
    Frenel, Jean-Sebastien
    Loaec, Cecile
    Bourgin, Charlotte
    Berton, Dominique
    Freyer, Gilles
    You, Benoit
    Classe, Jean-Marc
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 574 - 580
  • [28] The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands
    Van Wagensveld, L.
    Colomban, O.
    Van der Aa, M.
    Tod, M.
    Sonke, G. S.
    Kruitwagen, R.
    You, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S633 - S633
  • [29] Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy
    Prat, A.
    Parera, M.
    Peralta, S.
    Martinez, P.
    Adamo, B.
    Perez-Benavente, M.
    Gil-Moreno, A.
    Garcia, A.
    Martinez-Palones, J.
    Baselga, J.
    del Campo, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] DIFFERENT ANTIGENIC NATURE IN APPARENTLY HEALTHY WOMEN WITH HIGH SERUM CA-125 LEVELS COMPARED WITH TYPICAL PATIENTS WITH OVARIAN-CANCER
    HOSONO, MN
    ENDO, K
    SAKAHARA, H
    WATANABE, Y
    SAGA, T
    NAKAI, T
    HOSONO, M
    NAKAJIMA, T
    ONOYAMA, Y
    KONISHI, J
    CANCER, 1992, 70 (12) : 2851 - 2856
12345